Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYVIBE-010
2022-501417-31-00Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in cutaneous melanoma (CM) comparing Adjuvant MK-7684A (vibostolimab + pembrolizumab) with Adjuvant pembrolizumab (2 arms). Planned start Mar 2023; status: withdrawn.
02
Drugs
pembrolizumabvibostolimab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2022-501417-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501417-31-00.